| Followers | 38 |
| Posts | 4005 |
| Boards Moderated | 0 |
| Alias Born | 07/08/2002 |
Tuesday, June 15, 2021 10:42:06 AM
"We have likely missed the COVID play."
This description is fast becoming the de-facto line for LL. AND it is so untrue.
Less than 53% of the US population is fully vaccinated. And, judging from all the good/researched comments about the efficacy of vaccinations, my bet is that we are in the second inning of a loooooooong Covid game.
There is such ignorance about vaccinations that if anyone who is fully vaccinated believes that they don't have to wear a mask, especially when LL has not been approved for EUA, good luck with your healthy life.
Ask Eli Musser and a few others who were fortunate to have been inoculated with LL and claimed their life again.
I don't want to get the new Covid strain especially since there is CURRENTLY no known therapeutic that does what LL does beautifully. All these pharmas are trying and the FDA is allotting plenty of time so that they may develop a therapeutic like that recently approved Biogen drug.
Except for the fact that the Biogen drug is for dementia not Covid.
As I said, we are in the second inning of a long Covid game. A serious adversary. We have to win somewhere at some stage. Odds/greater numbers will dictate otherwise.
This description is fast becoming the de-facto line for LL. AND it is so untrue.
Less than 53% of the US population is fully vaccinated. And, judging from all the good/researched comments about the efficacy of vaccinations, my bet is that we are in the second inning of a loooooooong Covid game.
There is such ignorance about vaccinations that if anyone who is fully vaccinated believes that they don't have to wear a mask, especially when LL has not been approved for EUA, good luck with your healthy life.
Ask Eli Musser and a few others who were fortunate to have been inoculated with LL and claimed their life again.
I don't want to get the new Covid strain especially since there is CURRENTLY no known therapeutic that does what LL does beautifully. All these pharmas are trying and the FDA is allotting plenty of time so that they may develop a therapeutic like that recently approved Biogen drug.
Except for the fact that the Biogen drug is for dementia not Covid.
As I said, we are in the second inning of a long Covid game. A serious adversary. We have to win somewhere at some stage. Odds/greater numbers will dictate otherwise.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
